Your browser is no longer supported. Please, upgrade your browser.
Kura Oncology, Inc.
Index- P/E- EPS (ttm)-1.92 Insider Own2.94% Shs Outstand66.35M Perf Week-18.81%
Market Cap946.46M Forward P/E- EPS next Y-2.33 Insider Trans0.00% Shs Float62.75M Perf Month-16.04%
Income-123.90M PEG- EPS next Q-0.58 Inst Own- Short Float5.99% Perf Quarter-27.25%
Sales- P/S- EPS this Y-12.20% Inst Trans-1.72% Short Ratio6.00 Perf Half Y-37.06%
Book/sh8.04 P/B1.74 EPS next Y-12.00% ROA-20.50% Target Price45.67 Perf Year-60.63%
Cash/sh8.04 P/C1.74 EPS next 5Y19.93% ROE-21.60% 52W Range12.32 - 43.00 Perf YTD-57.12%
Dividend- P/FCF- EPS past 5Y-9.80% ROI- 52W High-67.44% Beta1.55
Dividend %- Quick Ratio25.00 Sales past 5Y- Gross Margin- 52W Low13.64% ATR0.98
Employees116 Current Ratio25.00 Sales Q/Q- Oper. Margin- RSI (14)24.96 Volatility7.35% 5.28%
OptionableYes Debt/Eq0.00 EPS Q/Q-19.30% Profit Margin- Rel Volume1.49 Prev Close14.01
ShortableYes LT Debt/Eq0.00 EarningsNov 04 AMC Payout- Avg Volume626.26K Price14.00
Recom1.70 SMA20-18.88% SMA50-22.74% SMA200-37.06% Volume442,329 Change-0.04%
May-05-21Resumed Credit Suisse Outperform $42
Apr-26-21Resumed Credit Suisse Outperform $42
Dec-07-20Reiterated H.C. Wainwright Buy $40 → $45
Dec-03-20Initiated Stifel Buy $45
Nov-05-20Downgrade Piper Sandler Overweight → Neutral
Jul-07-20Initiated Credit Suisse Outperform $27
May-05-20Initiated Barclays Overweight $24
Jul-18-19Initiated Deutsche Bank Buy $28
Nov-09-18Initiated Piper Jaffray Overweight
Aug-01-18Initiated H.C. Wainwright Buy $31
Oct-13-16Resumed Leerink Partners Outperform $15
Jan-22-16Initiated JMP Securities Mkt Outperform
Dec-30-15Initiated Oppenheimer Outperform $16
Dec-16-15Initiated Citigroup Buy
Nov-28-21 09:30PM  
Nov-25-21 11:34PM  
Nov-24-21 08:42PM  
Nov-23-21 07:30AM  
Nov-05-21 01:00PM  
Nov-04-21 04:05PM  
Nov-02-21 07:30AM  
Oct-28-21 07:30AM  
Oct-19-21 01:10PM  
Oct-18-21 07:30AM  
Sep-07-21 07:30AM  
Aug-17-21 08:07PM  
Aug-09-21 04:46AM  
Aug-06-21 02:30PM  
Aug-05-21 04:05PM  
Aug-04-21 07:30AM  
Jul-29-21 04:05PM  
Jul-06-21 07:30AM  
Jun-24-21 08:30AM  
Jun-10-21 07:30AM  
Jun-04-21 07:30AM  
May-13-21 07:30AM  
May-10-21 04:32PM  
May-07-21 02:00PM  
May-06-21 04:04PM  
Apr-29-21 07:30AM  
Mar-29-21 04:13PM  
Mar-22-21 04:08PM  
Feb-24-21 10:30PM  
Feb-18-21 07:30AM  
Feb-17-21 07:30AM  
Jan-25-21 02:50AM  
Jan-11-21 03:42PM  
Jan-07-21 07:30AM  
Jan-06-21 07:30AM  
Dec-22-20 09:29AM  
Dec-11-20 04:05PM  
Dec-10-20 07:30AM  
Dec-08-20 08:22PM  
Dec-07-20 04:01PM  
Dec-05-20 12:30PM  
Nov-24-20 07:30AM  
Nov-07-20 12:01AM  
Nov-05-20 07:30AM  
Nov-04-20 07:30AM  
Oct-29-20 07:30AM  
Oct-26-20 07:30AM  
Oct-07-20 07:30AM  
Sep-15-20 12:21AM  
Sep-08-20 07:30AM  
Aug-26-20 01:33PM  
Aug-25-20 07:30AM  
Aug-06-20 04:05PM  
Aug-04-20 07:30AM  
Jul-30-20 07:30AM  
Jul-29-20 10:23AM  
Jul-17-20 10:37AM  
Jun-16-20 10:46AM  
Jun-11-20 07:30AM  
May-29-20 08:00AM  
May-13-20 05:00PM  
May-08-20 04:03PM  
May-07-20 07:30AM  
May-06-20 09:00AM  
May-05-20 04:01PM  
May-04-20 04:05PM  
Apr-29-20 07:30AM  
Apr-28-20 03:09PM  
Mar-10-20 03:18AM  
Mar-03-20 07:30AM  
Feb-25-20 04:03PM  
Feb-19-20 04:05PM  
Feb-18-20 04:05PM  
Jan-24-20 10:44AM  
Jan-23-20 04:05PM  
Jan-21-20 04:09AM  
Jan-09-20 07:30AM  
Jan-06-20 07:30AM  
Dec-16-19 07:30AM  
Dec-10-19 02:21PM  
Dec-08-19 12:00PM  
Nov-26-19 07:30AM  
Nov-25-19 05:51AM  
Nov-15-19 04:29PM  
Nov-12-19 07:30AM  
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidates are tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications; and KO-539, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia. Kura Oncology, Inc. has a clinical collaboration with Novartis to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
FORD KATHLEENChief Operating OfficerMar 15Option Exercise19.436,250121,4386,250Mar 17 04:17 PM
FORD KATHLEENChief Operating OfficerMar 15Sale29.436,250183,9510Mar 17 04:17 PM
FORD KATHLEENChief Operating OfficerDec 15Option Exercise19.439,375182,1566,250Dec 16 04:02 PM
FORD KATHLEENChief Operating OfficerDec 15Sale40.609,375380,6670Dec 16 04:02 PM
WILSON TROY EDWARDPresident and CEODec 01Option Exercise6.1511,85572,90839,951Dec 02 04:04 PM